Antiretroviral treatment of HIV-2 infection

被引：4

作者：

de Mendoza, Carmen ^{[1
]}

Requena, Silvia ^{[1
]}

Caballero, Estrella ^{[2
]}

Cabezas, Teresa ^{[3
]}

Penaranda, Maria ^{[4
]}

Jose Amengual, Maria ^{[5
]}

Saez, Ana ^{[6
]}

Belen Lozano, Ana ^{[3
]}

Ramos, Jose M. ^{[7
]}

Soriano, Vincent ^{[8
,9
]}

机构：

[1] Puerta Hierro Res Inst, Lab Internal Med, Majadahonda, Spain

[2] Hosp Valle De Hebron, Dept Microbiol, Barcelona, Spain

[3] Hosp Poniente, Microbiol Unit, Almeria, Spain

[4] Son Espases Hosp, Microbiol Unit, Palma de Mallorca, Spain

[5] Corp Sanit Parc Tauli, Microbiol Unit, Sabadell, Spain

[6] Hosp Marques Valdecilla, Microbiol Unit, Santander, Spain

[7] Gen Hosp, Infect Dis Unit, Alicante, Spain

[8] La Paz Univ Hosp, Infect Dis Unit, Madrid, Spain

[9] Autonomous Univ Madrid, Madrid, Spain

来源：

FUTURE VIROLOGY | 2017年 / 12卷 / 08期

关键词：

antiretroviral therapy; dolutegravir; drug resistance; HIV-2; IMMUNODEFICIENCY-VIRUS TYPE-2; DRUG-RESISTANCE MUTATIONS; NAIVE HIV-2-INFECTED PATIENTS; HIGH-RISK GROUPS; REVERSE-TRANSCRIPTASE; COTE-DIVOIRE; VIRAL LOAD; IN-VITRO; THERAPY; INHIBITORS;

D O I：

10.2217/fvl-2017-0037

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

HIV-2 is a neglected virus despite estimates of 1-2 million people being infected worldwide. AIDS develops more slowly in HIV-2 than HIV-1. Outside endemic regions, HIV-2 is mostly found in immigrants from west Africa or their sex partners. There are four major caveats when treating HIV-2. First, some antiretrovirals are not or only partially active against HIV-2. Second, CD4 declines in HIV-2 occur slowly, but CD4 recovery is smaller with antiretroviral treatment. Third, both virological failure and rapid emergence of drug resistance occur more frequently in HIV-2 than HIV-1. Finally, misdiagnosis of HIV-2 in patients wrongly considered as infected with HIV-1 or in those dually infected may result in treatment failures with undetectable HIV-1 RNA. Integrase inhibitors, and especially dolutegravir, should be part of any preferred HIV-2 antiretroviral combination nowadays.

引用

页码：461 / 472

页数：12

共 85 条

[1] Antiretroviral therapy in HIV-2-infected patients:: changes in plasma viral load, CD4+cell counts, and drug resistance profiles of patients treated in Abidjan, Cote d'Ivoire [J].

Adjé-Touré, CA ;

Cheingsong, R ;

Garcìa-Lerma, JG ;

Eholié, S ;

Borget, MY ;

Bouchez, JM ;

Otten, RA ;

Maurice, C ;

Sassan-Morokro, M ;

Ekpini, RE ;

Nolan, M ;

Chorba, T ;

Heneine, W ;

Nkengasong, JN .

AIDS, 2003, 17 :S49-S54

[2] PROSPECTIVE COMPARISON OF MOTHER-TO-CHILD TRANSMISSION OF HIV-1 AND HIV-2 IN ABIDJAN, IVORY-COAST [J].

ADJORLOLOJOHNSON, G ;

DECOCK, KM ;

EKPINI, E ;

VETTER, KM ;

SIBAILLY, T ;

BRATTEGAARD, K ;

YAVO, D ;

DOORLY, R ;

WHITAKER, JP ;

KESTENS, L ;

OU, CY ;

GEORGE, JR ;

GAYLE, HD .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1994, 272 (06) :462-466

[3] HIV-2 Antiviral Potency and Selection of Drug Resistance Mutations by the Integrase Strand Transfer Inhibitor Elvitegravir and NRTIs Emtricitabine and Tenofovir In Vitro [J].

Andreatta, Kristen ;

Miller, Michael D. ;

White, Kirsten L. .

JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2013, 62 (04) :367-374

[4]

[Anonymous], 2017, TREATM GUID V8 2

[5]

[Anonymous], GUIDELINES USE ANTIR

[6]

Azevedo-Pereira JM, 2016, AIDS REV, V18, P44

[7] TMC278, a Next-Generation Nonnucleoside Reverse Transcriptase Inhibitor (NNRTI), Active against Wild-Type and NNRTI-Resistant HIV-1 [J].

Azijn, Hilde ;

Tirry, Ilse ;

Vingerhoets, Johan ;

de Bethune, Marie-Pierre ;

Kraus, Guenter ;

Boven, Katia ;

Jochmans, Dirk ;

Van Craenenbroeck, Elke ;

Picchio, Gaston ;

Rimsky, Laurence T. .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2010, 54 (02) :718-727

[8]

BABU PG, 1993, INDIAN J MED RES-A, V97, P49

[9] Immunovirological Response to Triple Nucleotide Reverse-Transcriptase Inhibitors and Ritonavir-Boosted Protease Inhibitors in Treatment-Naive HIV-2-Infected Patients: The ACHIEV2E Collaboration Study Group [J].

Benard, Antoine ;

van Sighem, Ard ;

Taieb, Audrey ;

Valadas, Emilia ;

Ruelle, Jean ;

Soriano, Vicente ;

Calmy, Alexandra ;

Balotta, Claudia ;

Damond, Florence ;

Brun-Vezinet, Francoise ;

Chene, Genevieve ;

Matheron, Sophie .

CLINICAL INFECTIOUS DISEASES, 2011, 52 (10) :1257-1266

[10] Baseline susceptibility of primary HIV-2 to entry inhibitors [J].

Borrego, Pedro ;

Calado, Rita ;

Marcelino, Jose M. ;

Bartolo, Ines ;

Rocha, Cheila ;

Cavaco-Silva, Patricia ;

Doroana, Manuela ;

Antunes, Francisco ;

Maltez, Fernando ;

Caixas, Umbelina ;

Barroso, Helena ;

Taveira, Nuno .

ANTIVIRAL THERAPY, 2012, 17 (03) :565-570

← 1 2 3 4 5 6 7 8 9 →